Aspira Women's Health, Inc. (NASDAQ:AWH) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Valerie Palmieri - CEO, President & Director Lesley Northrop - Global Medical Director, Genetic Services Robert Beechey - CFO Conference Call Participants Andrew Brackmann - William Blair & Company Operator Good afternoon, and welcome to Aspira Women's Health Second Quarter 2020 Conference Call. My name is Jessie, and I will be your coordinator for the call today. [Operator Instructions] ...

Financial Performance - Total revenue for Q2 2020 was $746,000, a decrease of 34.6% compared to $1,142,000 in Q2 2019[5]. - Gross profit for Q2 2020 was $153,000, down 34.6% from $234,000 in Q2 2019[5]. - Net loss for Q2 2020 was $3,831,000, compared to a net loss of $4,314,000 in Q2 2019, reflecting an 11.2% improvement[5]. - Total revenue for the three months ended June 30, 2020, was $746,000, a decrease of 35% compared to $1,142,000 for the same period in 2019[47]. - Gross profit for the three months ended June 30, 2020, was $153,000, a decrease of 35% from $234,000 in the same period in 2019[47]. - Net loss for the three months ended June 30, 2020, was $3,831,000, a decrease of 11% from $4,314,000 in the same period in 2019[47]. - The net loss for the six months ended June 30, 2020, was $7,537,000, compared to a net loss of $8,030,000 for the same period in 2019, indicating a slight improvement[8]. Revenue Breakdown - Product revenue for the first half of 2020 was $1,953,000, up from $1,879,000 in the same period of 2019, representing a 3.9% increase[5]. - Product revenue decreased by 32% to $743,000 for the three months ended June 30, 2020, primarily due to a decrease in the number of tests performed[47]. - The number of OVA1plus tests performed decreased by 21% to approximately 2,458 tests during the three months ended June 30, 2020, compared to approximately 3,129 tests for the same period in 2019[47]. Expenses - Operating expenses for Q2 2020 totaled $3,979,000, a decrease of 12.3% compared to $4,539,000 in Q2 2019[5]. - Total operating expenses for the three months ended June 30, 2020, were $3,979,000, a decrease of 12% from $4,539,000 in the same period in 2019[48]. - Sales and marketing expenses decreased by 38% to $1,733,000 for the three months ended June 30, 2020, compared to $2,780,000 for the same period in 2019[48]. - General and administrative expenses increased by 28% to $787,000 for the six months ended June 30, 2020, primarily due to increased headcount and legal expenses[52]. Cash and Liquidity - Cash and cash equivalents at the end of Q2 2020 were $10,935,000, down from $16,179,000 at the end of Q2 2019[8]. - Cash used in operating activities for the first half of 2020 was $6,910,000, compared to $6,652,000 in the same period of 2019[8]. - The accumulated deficit as of June 30, 2020, was approximately $429,698,000, highlighting ongoing financial challenges[9]. - The company reported a cash and cash equivalents balance of $10,935,000 at the end of the period, down from $16,179,000 at the end of the previous period[8]. COVID-19 Impact - The company experienced a significant decrease in test volume and revenue due to the COVID-19 pandemic, with a notable decline in late March and the second quarter of 2020[9]. - The company implemented virtual sales meetings and increased digital marketing efforts to adapt to the challenges posed by the pandemic[9]. - The company began running COVID-19 antibody tests in Q2 2020, utilizing Roche Elecsys Anti-SARS-CoV-2 Emergency Use Assay kits with 99.81% sensitivity and 100% specificity[38]. - The COVID-19 pandemic has impacted patient enrollment and commercial efforts, but the company has implemented virtual sales strategies to adapt[36]. Financing Activities - The company received approximately $89,000 from the U.S. Department of Health and Human Services under the CARES Act on April 10, 2020[10]. - The company obtained a Paycheck Protection Program loan of $1,005,767 from BBVA USA on May 1, 2020[10]. - The company completed a private placement of common stock on July 20, 2020, for gross proceeds of approximately $11 million before transaction costs[10]. - The company expects to raise additional capital through various sources, including equity offerings and strategic alliances[54]. Research and Development - Research and development expenses increased to $380,000 in Q2 2020, up from $225,000 in Q2 2019, marking a 68.9% increase[5]. - The company plans to broaden its commercial focus from ovarian cancer to a range of gynecological disorders, including the development of new algorithms and molecular diagnostic tests[28]. - The company is developing three additional diagnostic products: OVANex™, EndoCheck™, and OVAInherit™, targeting pelvic masses and endometriosis detection[33]. Product Development and Market Strategy - OVA1 and Overa products have received FDA clearance, with OVA1 launched in September 2009 and Overa in March 2016[33]. - The company aims to transform women's health globally, focusing on ovarian cancer and providing personalized risk assessment solutions[32]. - The company is leveraging its existing database to build the largest specimen and data repository of gynecologic pelvic mass patients worldwide, enhancing research and development efforts[40]. - ASPiRA LABS launched OVA1plus in October 2018, combining OVA1 and Overa to drive earlier detection of ovarian cancer, which can lower overall healthcare costs[41].

Vermillion, Inc. (VRML) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Valerie Palmieri – President and Chief Executive Officer Chris Goulart – Senior Vice President of Commercial Operations Bob Beechey – Chief Financial Officer Conference Call Participants Brian Weinstein – William Blair Jeb Terry – Aberdeen Investment Management Kyle Mikson – Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to Vermillion's First Quarter 2020 Conference Call. My na ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Vermillion, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0595156 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-34810 Vermillion, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0595156 (State or Other Jurisd ...

VRML (VRML) Q4 2019 Results Conference Call March 26, 2020 4:30 PM ET Company Participants Valerie Palmieri - President and CEO Bob Beechey - CFO Chris Goulart - SVP, Commercial Operations Conference Call Participants Jeb Terry - Aberdeen Investment Management Jack Fraser - Seamark Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Vermillion’s Fourth Quarter 2020 (sic) [2019] Conference Call. My name is Doug, and I will be your coordinator for the call today. At this time, all partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION | --- | --- | |--------------|------------------------------------------| | | WASHINGTON, D.C. 20549 \nFORM 10-Q | | (Mark One) | | ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 VERMILLION® Ver ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION | --- | --- | --- | |--------------|---------------------------|--------------| | | WASHINGTON, D.C. \nFORM | 20549 \n10-Q | | (Mark One) | | | ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 VERMILLI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION | --- | --- | --- | |--------------|----------------------------------------|-------| | | WASHINGTON, DC 20549 \nFORM 10-Q | | | (Mark One) | | | ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-34810 VERMI ...